Real-world Persistence of Ofatumumab vs Self-injectable or Oral Disease-modifying Therapies in Patients with Multiple Sclerosis
Carrie Hersh1, Magdaliz Gorritz2, Chi-Chang Chen2, Rifat Tuly2, Yifan Gu2, Qiujun Shao3, Abhijit Gadkari3, Brandon Brown3
1Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA, 2IQVIA, Plymouth Meeting, PA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Objective:
To compare the real-world persistence of ofatumumab vs platform self-injectable or oral disease-modifying therapies (DMTs).
Background:
Ofatumumab is approved for relapsing forms of multiple sclerosis (MS). Real-world evidence on the persistence of ofatumumab compared with self-injectable or oral DMTs is limited.
Design/Methods:
This was a retrospective cohort study using a longitudinal health plan database of medical and pharmacy claims in the United States (IQVIA PharMetrics Plus). Adults diagnosed with MS and treated with ofatumumab, a platform self-injectable (glatiramer acetate, interferon β-1a/1b, or peginterferon β-1a), or an oral DMT (dimethyl fumarate, fingolimod, teriflunomide, cladribine, siponimod, ozanimod, diroximel fumarate, and monomethyl fumarate) between August 2020 and November 2021 and who had ≥6 months of follow-up were included. First pharmacy claim for index treatment was defined as the index date. Persistence was defined as the number of days from the index date until the earliest time of discontinuation (>60-day gap) or a switch to a new DMT. Propensity score matching reduced possible confounding by baseline demographics and disease characteristics. Sensitivity analyses using 90 days as the allowed gap were conducted.
Results:
The matched cohorts included 576 ofatumumab patients, 592 platform self-injectable DMT patients, and 576 oral DMT patients. Patients had a mean age of ~47 years. Additionally, ~79% were female, and ~94% were commercially insured. For ofatumumab vs self-injectable DMTs, respectively, 80.8% vs 56.7% were persistent at 6 months and 74.5% vs 43.2% were persistent at 12 months (both comparisons, p<0.001). For ofatumumab vs oral DMTs, respectively, 81.9% vs 77.8% were persistent at 6 months and 76.3% vs 64.6% were persistent at 12 months (both comparisons, p=0.002). Results remained consistent after sensitivity analyses.
Conclusions:
In this real-world study with 12 months of follow-up, patients treated with ofatumumab demonstrated higher persistence vs those treated with platform self-injectable DMTs and those treated with oral DMTs.